44 related articles for article (PubMed ID: 33097970)
21. To evaluate prognostic significance of metabolic-derived tumour volume at staging 18-flurodeoxyglucose PET-CT scan and to compare it with standardized uptake value-based response evaluation on interim 18-flurodeoxyglucose PET-CT scan in patients of non-Hodgkin's lymphoma (diffuse large B-cell lymphoma).
Gupta N; Singh N
Nucl Med Commun; 2020 Apr; 41(4):395-404. PubMed ID: 32073552
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
23. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
24. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of the baseline 18F-FDG PET/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL.
Zhao P; Yu T; Pan Z
Ann Nucl Med; 2021 Jan; 35(1):24-30. PubMed ID: 33001389
[TBL] [Abstract][Full Text] [Related]
26. Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma.
St-Pierre F; Broski SM; LaPlant BR; Ristow K; Maurer MJ; Macon WR; Habermann TM; Ansell SM; Thompson CA; Micallef INM; Nowakowski GS; Witzig TE
Am J Hematol; 2019 Jul; 94(7):786-793. PubMed ID: 31006875
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis.
Guo B; Tan X; Ke Q; Cen H
PLoS One; 2019; 14(1):e0210224. PubMed ID: 30625203
[TBL] [Abstract][Full Text] [Related]
28. Methodological Aspects and the Prognostic Value of Metabolic Tumor Volume assessed with 18F-FDG PET/CT in Lymphomas.
Tutino F; Giovannini E; Pastorino S; Ferrando O; Giovacchini G; Ciarmiello A
Curr Radiopharm; 2022; 15(4):259-270. PubMed ID: 35352655
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis.
Adams HJ; Kwee TC
Crit Rev Oncol Hematol; 2016 Oct; 106():55-63. PubMed ID: 27637352
[TBL] [Abstract][Full Text] [Related]
30. 18F-FDG PET/CT in the diagnosis of an extranodal relapse of diffuse large B-cell lymphoma (DLBCL): a clinical case with a literature review.
Chaushev B; Micheva I; Mechmed M; Balev B; Bocheva Y; Ivanova D; Krasnaliev I; Lozanova R; Klisarova A; Bochev P; Dancheva J
Nucl Med Rev Cent East Eur; 2016; 19(B):11-13. PubMed ID: 27813622
[TBL] [Abstract][Full Text] [Related]
31. [Role of Interim 18
Lu XL; Zhu HY; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Aug; 25(4):1241-1244. PubMed ID: 28823301
[TBL] [Abstract][Full Text] [Related]
32. FDG-PET for Early Response Assessment in Lymphomas: Part 2-Diffuse Large B-Cell Lymphoma, Use of Quantitative PET Evaluation.
Cheson BD; Kostakoglu L
Oncology (Williston Park); 2017 Jan; 31(1):71-76. PubMed ID: 28090627
[TBL] [Abstract][Full Text] [Related]
33. [The role of PET/CT investigation in the management of patients with diffuse large B-cell lymphoma].
Paksi M; Demeter J; Szabó P
Magy Onkol; 2016 Jun; 60(2):108-17. PubMed ID: 27275637
[TBL] [Abstract][Full Text] [Related]
34. Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma.
Mylam KJ; Nielsen AL; Pedersen LM; Hutchings M
PET Clin; 2014 Oct; 9(4):443-55, vi. PubMed ID: 26050946
[TBL] [Abstract][Full Text] [Related]
35. Pre-treatment total metabolic tumour volumes in lymphoma: Does quantity matter?
El-Galaly TC; Villa D; Cheah CY; Gormsen LC
Br J Haematol; 2022 Apr; 197(2):139-155. PubMed ID: 35037240
[TBL] [Abstract][Full Text] [Related]
36. Jaundice may be the only clinical manifestation of primary hepatosplenic diffuse large B-cell lymphoma: a case report and literature review.
Shi X; Zhang T; Xu H; Zhang X; Zhao H; Liu X; Hou F; Yang G; Liu Z
J Int Med Res; 2020 Aug; 48(8):300060520938173. PubMed ID: 32762403
[TBL] [Abstract][Full Text] [Related]
37. The new German evidence-based guideline on diffuse large B-cell lymphoma-key aspects for radiation oncologists.
Oertel M; Berdel C; Held G; Herfarth K; Schmidberger H; Ernst M; Lenz G; Borchmann P; Eich HT
Strahlenther Onkol; 2023 Feb; 199(2):115-120. PubMed ID: 36598520
[TBL] [Abstract][Full Text] [Related]
38. The prognostic significance of whole-body and spleen MTV (metabolic tumor volume) scanning for patients with diffuse large B cell lymphoma.
Yamanaka S; Miyagawa M; Sugawara Y; Hasebe S; Fujii T; Takeuchi K; Tanaka K; Yakushijin Y
Int J Clin Oncol; 2021 Jan; 26(1):225-232. PubMed ID: 33097970
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]